Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 767-771

  Stohr W ^a   Langer, T ^a   Kremers, A ^a   Brecht, I ^b   Treuner, J ^b   Dinnesen, A ^c   Beck, J D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b OLGAHOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Carboplatin; Childhood cancer; Late effects; Ototoxicity; Soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN;

ADOLESCENT; ADULT; ARTICLE; AUDIOMETRY; CHILD; CLINICAL TRIAL; HEARING LOSS; HUMAN; INCIDENCE; MULTICENTER STUDY; PROSPECTIVE STUDY; SARCOMA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CARBOPLATIN; CHILD; HEARING LOSS; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; SARCOMA;

EID: 16644377519     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.4.767     Document Type: Article

References (32)

1. Schweitzer VG: Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 26: 759-789, 1993.
2. Delb W, Feilen S, Koch A and Federspil P: Comparative studies of the ototoxicity of cisplatin and carboplatin. Laryngorhinootologie 72: 24-27, 1993. (Pubitemid 23051216)
3. Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ and Sheridan C: Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM- 9). Otolaryngol Head Neck Surg 94: 458-470, 1986. (Pubitemid 16043930)
4. Taudy M, Syka J, Popelar J and Ulehlova L: Carboplatin and cisplatin ototoxicity in guinea pigs. Audiology 31: 293-299, 1992.
5. Watanabe KC, Jinnouchi K, Hess A, Michel O, Baba S and Yagi T: Carboplatin induces less apoptosis in the cochlea of guinea pigs than cisplatin. Chemotherapy 48: 82-87, 2002. (Pubitemid 34507600)
6. Canetta R, Franks C, Smaldone L, Bragman K and Rozencweig M: Clinical status of carboplatin. Oncology 1: 61-70, 1987.
7. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245-1251, 1992.
8. Friedman HS, Krischer JP, Burger P, et al: Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10: 249-256, 1992.
9. Horwich A, Dearnaley DP, Nicholls J, et al: Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 9: 62-69, 1991.
10. Lopez-Aguilar E, Sepulveda-Vildosola AC, Rivera-Marquez H, et al: Survival of patients with medulloblastoma treated with carboplatin and etoposide before and after radiotherapy. Arch Med Res 29: 313-317, 1998. (Pubitemid 29004964)
11. Meyer WH, Pratt CB, Poquette CA, et al: Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 19: 171-182, 2001. (Pubitemid 32063494)
12. Bauer FP, Westhofen M and Kehrl W: The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors. Laryngorhinootologie 71: 412-415, 1992.
13. De Lauretis A, De Capua B, Barbieri MT, Bellussi L and Passali D: ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand Audiol 28: 139-143, 1999. (Pubitemid 29403381)
14. Kennedy IC, Fitzharris BM, Colls BM and Atkinson CH: Carboplatin is ototoxic. Cancer Chemother Pharmacol 26: 232-234, 1990. (Pubitemid 20191203)
15. Macdonald MR, Harrison RV, Wake M, Bliss B and Macdonald RE: Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 23: 151-159, 1994. (Pubitemid 24238760)
16. van der Hulst RJ, Dreschler WA and Urbanus NA: High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 97: 133-137, 1988.
17. Wandt H, Birkmann J, Denzel T, at el: Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23: 763-770, 1999. (Pubitemid 29186885)
18. Langer T, Henze G and Beck J: Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 34: 348-351, 2000. (Pubitemid 30230610)
19. Langer T, Stohr W, Bielack S, Paulussen M, Treuner J and Beck JD: Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42: 373-379, 2004. (Pubitemid 38327633)
20. Peters U, Preisler-Adams S, Lanvers-Kaminsky C, Jurgens H and Lamprecht-Dinnesen A: Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 23: 1249-1255, 2003. (Pubitemid 36754084)
21. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE and Hammond GD: A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 73: 1297-1301, 1994. (Pubitemid 24061630)
22. Frappaz D, Michon J, Hartmann O, et al: Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 10: 1592-1601, 1992. (Pubitemid 23057989)
23. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD and Hammond GD: Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer 66: 2465-2469, 1990.
24. Heideman RL, Kovnar EH, Kellie SJ, et al: Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13: 2247-2254, 1995.
25. Aguilar-Markulis NV, Beckley S, Priore R and Mettlin C: Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 16: 111-123, 1981. (Pubitemid 11125717)
26. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA and Kanz L: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355-1362, 1998. (Pubitemid 28140629)
27. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR and Pritchard J: Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19: 295-300, 1991.
28. Ilveskoski I, Saarinen UM, Wiklund T, et al: Ototoxicity in children with malignant brain tumors treated with the '8 in 1' chemotherapy protocol. Med Pediatr Oncol 27: 26-31, 1996.
29. Ruiz L, Gilden J, Jaffe N, Robertson R and Wang YM: Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum(II). Cancer Res 49: 742-744, 1989. (Pubitemid 19050346)
30. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M and Meyer WH: Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7: 754-760, 1989. (Pubitemid 19145597)
31. Hartmann S, Schäper E, Lamprecht-Dinnesen A and Boos J: Ototoxizität von Cisplatin im Kindesalter. Otorhinolaryngol Nova 5: 222-230, 1995.
32. McHaney VA, Thibadoux G, Hayes FA and Green AA: Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 102: 314-317, 1983. (Pubitemid 13194726)